Novo Nordisk (NVO) shares crashed on Tuesday after the Danish drugmaker issued a sobering outlook for 2026 that caught Wall Street flat-footed. According to the pharma giant, its top- and bottom-line growth will decelerate this year as its “Most Favored Nations” agreement with the U.S. lowers weight-loss drug prices in its largest market. More News from Barchart At the time of writing, Novo Nordisk stock is trading some 20% below its year-to-date high. www.barchart.com What This 2026 Outlook Really M ...